Sujentec Signs Distribution Agreement with 'CelltrionUSA'... "Accelerating Entry into the US Market"

[Asia Economy Reporter Hyunseok Yoo] SuzenTec announced on the 11th that it has signed a distribution agreement with 'Celltrion USA' for the 'COVID-19 Antibody Rapid Test Kit Using Capillary Blood.'

The product covered by this sales agreement is the 'TekiTrust COVID-19 IgG Rapid Test,' which is a dedicated product for Celltrion's US subsidiary based on the 'SGTi-flex Covid-19 IgG,' the first domestic company product to receive Emergency Use Authorization from the US FDA in April for CLIA (Clinical Laboratory Improvement Amendments) waived Point of Care Testing (POCT) using capillary blood.

Unlike existing products used only in large hospitals with laboratory facilities, CLIA-waived products can be used not only in professional laboratories but also in small hospitals and pharmacies staffed with medical personnel, enabling supply through various distribution channels.

As many countries worldwide are considering the introduction of COVID-19 'vaccine passports' and 'immunity passports,' antibody testing can immediately determine immune formation after vaccination, asymptomatic infection confirmation, and infection history verification, leading to a significant increase in demand for antibody rapid test kits.

A SuzenTec official stated, "With this contract with Celltrion's US subsidiary, we can enter various US distribution channels owned by Celltrion," adding, "Recently, the vaccination rate for at least one dose in the US has exceeded 50%, and antibody testing is beginning to be recognized as an essential procedure when entering crowded public places, causing a rapid increase in demand for antibody rapid test kits."

He continued, "This contract allows us to diversify our sales structure, which was previously focused on Europe," and said, "We will do our best to expand US sales centered on antibody rapid test kits."